MedElevator
Войти в исследования AIDS (London, England) · 2026
Determinants of long-acting cabotegravir plus rilpivirine discontinuation in real-world HIV care: insights from the relativity cohort.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Troya Jesús, Montes María Luisa, Galindo María José, Sánchez-López María Belén, Pelazas-González Ricardo, Torralba Miguel, Díaz de Santiago Alberto, Fanjul Francisco, Rodríguez Adrián, Cabello Alfonso, Crusells-Canales María José, Navarro María Del Carmen, Aguilera María, Hidalgo Carmen, Morano Luis Enrique, Vinuesa-García David, David Carlos De Andrés, Bernal Enrique, Martínez-Álvarez Rosa María, Romero Alberto, Tiraboschi Juan, Gimeno-García Alejandra, Ferreira Eva María, Losa-García Juan Emilio, Pedrero-Tomé Roberto, Buzón-Martín Luis
Аннотация
OBJECTIVES: To evaluate real-world persistence with long-acting cabotegravir plus rilpivirine (CAB+RPV LA) in a nationwide cohort of virologically suppressed adults, describe the main clinical and structural reasons for discontinuation, and identify predictors of early interruption in routine practice.
DESIGN: Ambispective, multicenter cohort study assessing the durability, safety, adherence, and virological outcomes of CAB+RPV LA implementation across 58 Spanish healthcare settings.
METHODS: Adults initiating CAB+RPV LA therapy were enrolled using standardized electronic tools. Baseline demographics, comorbidities, HIV and virological variables, and injection timing were recorded. Permanent discontinuations were attributed to systemic adverse events, injection-site reactions, virological failure (VF), or nonclinical causes. The virological endpoints were aligned, although not identical, to the CONSENSUS-LAI criteria. Kaplan-Meier curves and multivariate Cox models were used to identify the independent predictors.
RESULTS: Among 3146 virologically suppressed participants, 199 (6.3%) permanently discontinued therapy over a median 13.8-month follow-up. Discontinuation was more frequent among women (21.6 vs. 14.4%; P = 0.007), foreign-born individuals (42.9 vs. 29.5%; P < 0.001), those with a higher BMI, and those with shorter prior suppression periods. injection-site reaction- and systemic adverse event-related discontinuations were rare (1.2 and 0.7%, respectively), whereas structural reasons accounted for 3.5%. VF occurred in 20 participants (0.6%). Adjusted analyses showed that age ≥70 years [hazard ratio (HR) 5.41; 95% confidence interval (CI) 1.91-15.32] and foreign nationality (HR 2.06; 95% CI 1.48-2.86) independently increased discontinuation risk, whereas male sex (HR 0.65; 95% CI 0.44-0.96) and longer suppression (HR/day 0.99; P = 0.036) were protective.
CONCLUSIONS: In this large national cohort, CAB+RPV LA demonstrated strong persistence, excellent tolerability, and very low rates of VF. Discontinuations were mainly structural, highlighting the need to reinforce continuity-of-care pathways and system-level support for optimal CAB+RPV LA scale-up.
DESIGN: Ambispective, multicenter cohort study assessing the durability, safety, adherence, and virological outcomes of CAB+RPV LA implementation across 58 Spanish healthcare settings.
METHODS: Adults initiating CAB+RPV LA therapy were enrolled using standardized electronic tools. Baseline demographics, comorbidities, HIV and virological variables, and injection timing were recorded. Permanent discontinuations were attributed to systemic adverse events, injection-site reactions, virological failure (VF), or nonclinical causes. The virological endpoints were aligned, although not identical, to the CONSENSUS-LAI criteria. Kaplan-Meier curves and multivariate Cox models were used to identify the independent predictors.
RESULTS: Among 3146 virologically suppressed participants, 199 (6.3%) permanently discontinued therapy over a median 13.8-month follow-up. Discontinuation was more frequent among women (21.6 vs. 14.4%; P = 0.007), foreign-born individuals (42.9 vs. 29.5%; P < 0.001), those with a higher BMI, and those with shorter prior suppression periods. injection-site reaction- and systemic adverse event-related discontinuations were rare (1.2 and 0.7%, respectively), whereas structural reasons accounted for 3.5%. VF occurred in 20 participants (0.6%). Adjusted analyses showed that age ≥70 years [hazard ratio (HR) 5.41; 95% confidence interval (CI) 1.91-15.32] and foreign nationality (HR 2.06; 95% CI 1.48-2.86) independently increased discontinuation risk, whereas male sex (HR 0.65; 95% CI 0.44-0.96) and longer suppression (HR/day 0.99; P = 0.036) were protective.
CONCLUSIONS: In this large national cohort, CAB+RPV LA demonstrated strong persistence, excellent tolerability, and very low rates of VF. Discontinuations were mainly structural, highlighting the need to reinforce continuity-of-care pathways and system-level support for optimal CAB+RPV LA scale-up.